Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis

Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis

To examine the potential benefits and adverse events of neoadjuvant Chemoradiotherapy (CRT) versus upfront surgery in pancreatic cancer (PC) patients. Extensive librarian-led literature searches were conducted on PubMed, Web-of-Science, Scopus, Google Scholar, the Cochrane Central Library and Embase...

Full description

Bibliographic Details
Main Authors:	Wenhao Luo, Yawen Wang, Yinjie Tao, Taiping Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Oncology
Subjects:	neoadjuvant CRT upfront surgery overall survival adverse events complication events
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.979390/full

Similar Items

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
by: Lingyu Zhu, et al.
Published: (2023-08-01)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
by: Hyun Jeong Jeon, et al.
Published: (2023-08-01)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
by: Zijiao Yang, et al.
Published: (2023-04-01)

Comparison of post-operative complications in oral cancer treated with and without neoadjuvant chemotherapy
by: Mridul Kumar Sarma, et al.
Published: (2023-01-01)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
by: Alessandro Coppola, et al.
Published: (2023-05-01)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
by: Eric Zandirad, et al.
Published: (2022-11-01)

Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma
by: Tadataka Takagi, et al.
Published: (2023-03-01)

Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy
by: Simone Famularo, et al.
Published: (2023-01-01)

Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
by: Bitenc Marko, et al.
Published: (2022-08-01)

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
by: Shigeo Shimose, et al.
Published: (2022-09-01)

Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of  Operable Stage III NSCLC
by: Yun ZHANG, et al.
Published: (2023-06-01)

Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
by: Huaiyong WANG, et al.
Published: (2023-11-01)

Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis
by: Qi Ling, et al.
Published: (2023-12-01)

Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1–2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
by: Seung Eun Lee, et al.
Published: (2023-05-01)

The Comparative Effect of Definitive Chemoradiotherapy and Neoadjuvant Chemoradiotherapy Plus Surgery on One-Year Survival Rate of Esophageal Cancer Patients
by: Fatemeh Khanaki, et al.
Published: (2022-12-01)

Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
by: Yuqian Feng, et al.
Published: (2024-01-01)

Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas
by: Małgorzata Domagała-Haduch, et al.
Published: (2023-04-01)

Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible
by: Xiaoting Ma, et al.
Published: (2023-11-01)

Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
by: Chie Takasu, et al.
Published: (2022-12-01)

The Implementation of a Complication Avoidance Care Bundle Significantly Reduces Adverse Surgical Outcomes in Orthopedic Trauma Patients
by: Thomas Lustenberger, et al.
Published: (2020-12-01)

Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer
by: Jianguo Yang, et al.
Published: (2023-03-01)

LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)
by: Katerina Maliarchuk, et al.
Published: (2022-12-01)

The role of neoadjuvant chemotherapy in patients with locally advanced colon cancer: A systematic review and meta-analysis
by: Zongyu Liang, et al.
Published: (2022-10-01)

The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
by: Changyuan Wang, et al.
Published: (2023-11-01)

Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis
by: Yu Xia, et al.
Published: (2023-12-01)

Introducing upfront losses as well as gains decreases impatience in intertemporal choices with rewards
by: Cheng-Ming Jiang, et al.
Published: (2014-07-01)

Predictive Factors of Long-Term Survival after Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer
by: Jan Haussmann, et al.
Published: (2022-08-01)

Appraisal of Intraoperative Adverse Events to Improve Postoperative Care
by: Larsa Gawria, et al.
Published: (2023-03-01)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
by: Sara Franzi, et al.
Published: (2022-05-01)

Introducing upfront losses as well as gains decreases impatience in intertemporal choices with rewards
by: Cheng-Ming Jiang, et al.
Published: (2014-07-01)

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
by: Qi Cai, et al.
Published: (2022-12-01)

Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: Retrospective Single-Center Study
by: Liliana Mereu, et al.
Published: (2023-10-01)

Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
by: Alessandro Coppola, et al.
Published: (2022-08-01)

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
by: Yuwen Qi, et al.
Published: (2023-08-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
by: Damir Vucinic, et al.
Published: (2024-03-01)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021-01-01)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
by: Guang-Tan Lin, et al.
Published: (2022-12-01)

Is it a complication or a consequence - a new perspective on adverse outcomes in Interventional Radiology
by: Anna Maria Ierardi, et al.
Published: (2024-01-01)

Complications in Interventional Radiology: the role of clinical governance and iterative hospital systems in quality improvement
by: Warren Clements, et al.
Published: (2023-08-01)

How We Treat Localized Rectal Cancer—An Institutional Paradigm for Total Neoadjuvant Therapy
by: Falk Roeder, et al.
Published: (2022-11-01)